Lundbeck set to add Abide’s chemo-proteomic platform for $400m

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Radachynskyi)
(Image: Getty/Radachynskyi)

Related tags: Lundbeck, Abide Therapeutics, Neuroscience

Lundbeck announces the acquisition of Abide, which provides the former with access to an R&D platform, a Phase II drug candidate, and drug discovery site in California.

The deal sees Lundbeck set to pay $250m (€223m) upfront for Abide Therapeutics while also holding a further payment of $150m in reserve, dependent on development and commercial milestones being hit.

Abide’s work is focused on serine hydrolases, which play a role in controlling levels of bioactive signalling molecules, such as lipids, neurotransmitters, peptides, and proteins.

Lundbeck will acquire the drug candidate ABX-1431, Abide’s lead candidate, which is currently in Phase IIa trials for the treatment of Tourette’s syndrome and Phase I for neuropathic pain.

A spokesperson for Lundbeck told us that its short-term development plan is to pursue these two indications, but added, in the long-term, the candidate may have the potential for other neurologic and psychiatric diseases.

ABX-1431 inhibits serine hydrolase monoacylglycerol lipase, which the company states “potentiates endocannabinoid signalling to restore homeostatic balance in the central nervous system.”

Alongside the lead candidate, Abide will bring with it a chemo-proteomic platform that it has used to build a pipeline​ of clinical and pre-clinical candidates.

Deborah Dunsire, CEO of Lundbeck, said, “Abide’s innovative R&D platform provides us with a unique opportunity to strengthen our pipeline now and well into the future, putting Lundbeck in position to deliver multiple new and transformative treatments for brain diseases.”

The acquisition also sees Lundbeck add Abide’s laboratory in La Jolla, US, to its business infrastructure, by converting the space into a ‘drug discovery hub’. However, the site was secondary to the pursuit of the deal, which was foremost due to the quality of the science and the R&D platform, the spokesperson explained.

The deal will be secured through the use of Lundbeck’s existing cash reserves and is expected to close in the second quarter of 2019.

Related news

Related products

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers